Antitumor necrosis factor α antibodies (anti-TNFα Abs) constitute a major advance in rheumatoid arthritis (RA) therapy in the clinic, as targeting TNFα in the disease region can reduce pathological inflammation and efficiently inhibit RA progression [1]. This evidence concerns the gene TNF and rheumatoid arthritis.